| Literature DB >> 18091319 |
Christopher J Johnson1, Michelle B Barry, Mohammad A Vasef, Barry R Deyoung.
Abstract
Salivary duct carcinoma (SDC) shares significant morphologic and immunophenotypic overlap with ductal carcinoma of the breast, including HER-2/neu expression. Previous studies have detected HER-2/neu at the protein level in SDCs; however, no study, to date, has assayed whether this expression is related to gene amplification detected by chromogenic in situ hybridization (CISH). Formalin-fixed, paraffin-embedded tissue sections from 12 previously diagnosed SDCs were evaluated by immunohistochemistry (IHC) and CISH for HER-2/neu status. Result concordance was seen in all 12 cases. A total of 4 SDCs were positive by IHC; all 4 cases showed amplification with CISH. The remaining 8 cases were negative by IHC and showed no gene amplification with CISH. SDCs in this study show HER-2/neu overexpression on both the protein and gene levels in approximately 30% of cases. These findings suggest a role may exist for Herceptin (trastuzumab) based therapy in some SDC patients.Entities:
Mesh：
Substances：
Year: 2008 PMID： 18091319 DOI： 10.1097/PAI.0b013e31802e91b2
Source DB: PubMed Journal: Appl Immunohistochem Mol Morphol ISSN： 1533-4058